These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37277195)

  • 41. Advancing development of medical countermeasures: Incorporating COVID-19 lessons learned into future pandemic preparedness planning.
    Johnson RA; White RC; Disbrow GL
    Hum Vaccin Immunother; 2022 Nov; 18(6):2129930. PubMed ID: 36302122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Forty days of regulatory emergency use authorisation of COVID-19 vaccines: Interfacing efficacy, hesitancy and SDG target 3.8.
    Nhamo G; Sibanda M
    Glob Public Health; 2021 Oct; 16(10):1537-1558. PubMed ID: 34105432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study.
    Lalani HS; Nagar S; Sarpatwari A; Barenie RE; Avorn J; Rome BN; Kesselheim AS
    BMJ; 2023 Mar; 380():e073747. PubMed ID: 36858453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions.
    Tagoe ET; Sheikh N; Morton A; Nonvignon J; Sarker AR; Williams L; Megiddo I
    Front Public Health; 2021; 9():709127. PubMed ID: 34422750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An equitable vaccine delivery system: Lessons from the COVID-19 vaccine rollout in Canada.
    Kholina K; Harmon SHE; Graham JE
    PLoS One; 2022; 17(12):e0279929. PubMed ID: 36584230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How manufacturing won or lost the COVID-19 vaccine race.
    King ML
    Vaccine; 2024 Feb; 42(5):1004-1012. PubMed ID: 38228438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges.
    Hanney SR; Straus SE; Holmes BJ
    Health Res Policy Syst; 2022 Sep; 20(1):99. PubMed ID: 36088365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19 Vaccines in Older Adults: Challenges in Vaccine Development and Policy Making.
    Liang CK; Lee WJ; Peng LN; Meng LC; Hsiao FY; Chen LK
    Clin Geriatr Med; 2022 Aug; 38(3):605-620. PubMed ID: 35868676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.
    Peacocke EF; Heupink LF; Frønsdal K; Dahl EH; Chola L
    BMJ Open; 2021 Sep; 11(9):e049505. PubMed ID: 34593496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risky business: COVAX and the financialization of global vaccine equity.
    Stein F
    Global Health; 2021 Sep; 17(1):112. PubMed ID: 34544439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
    Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accelerating clinical trial development in vaccinology: COVID-19 and beyond.
    Corey L; Miner MD
    Curr Opin Immunol; 2022 Jun; 76():102206. PubMed ID: 35569415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Call to Action Against Persistent Lack of Transparency in Vaccine Pricing Practices During the COVID-19 Pandemic.
    Arguedas-Ramírez G
    Ann Glob Health; 2022; 88(1):87. PubMed ID: 36311897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Cross-sectional Survey of Public Knowledge and Perspective on Coronavirus Disease, Vaccination, and Related Research in India during the COVID-19 Pandemic.
    Munshi R; Maurya M
    J Assoc Physicians India; 2023 Sep; 71(9):19-27. PubMed ID: 38700297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pandemics, intellectual property and 'our economy': A worldview analysis of Canada's role in compromising global access to COVID-19 vaccines.
    Brisbois B; Plamondon K; Walugembe D; Pereira RC; Edet C; Dixon J; Habibi R; Karamouzian M; Labonté R; Murthy S; Ravitsky V
    Glob Public Health; 2024 Jan; 19(1):2335360. PubMed ID: 38626321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accelerating research and development of new vaccines against tuberculosis: a global roadmap.
    Cobelens F; Suri RK; Helinski M; Makanga M; Weinberg AL; Schaffmeister B; Deege F; Hatherill M;
    Lancet Infect Dis; 2022 Apr; 22(4):e108-e120. PubMed ID: 35240041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current and future nanoparticle vaccines for COVID-19.
    Vu MN; Kelly HG; Kent SJ; Wheatley AK
    EBioMedicine; 2021 Dec; 74():103699. PubMed ID: 34801965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Access to COVID-19 vaccines and testing in Africa: the importance of COVAX - Nigeria as a case study.
    Grenfell RFQ; Oyeyemi OT
    Pathog Glob Health; 2023 Mar; 117(2):152-166. PubMed ID: 35770309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe.
    Wagner R; Meißner J; Grabski E; Sun Y; Vieths S; Hildt E
    Allergy; 2022 Jan; 77(1):72-82. PubMed ID: 33887070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Upscaling vaccine manufacturing capacity - key bottlenecks and lessons learned.
    Feddema JJ; Fernald KDS; Schikan HGCP; van de Burgwal LHM
    Vaccine; 2023 Jul; 41(30):4359-4368. PubMed ID: 37277250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.